|
|
 |
ADEPT® [4% Icodextrin] Solution |
|
|
|
![ADEPT<sup>®</sup>[4% Icodextrin] Solution](/images/products/biopharmaceuticals/AdeptIcon.jpg)
|
ADEPT® is an icodextrin solution that keeps the peritoneal surfaces apart during the critical post-surgery period when the patient is at greatest risk of adhesion formation following laparoscopic gynecologic adhesiolysis.1,2
|
|
|
|
|
|
|
|
|
|
- ADEPT® Adhesion Reduction Solution [4% Icodextrin] is indicated for use intraperitoneally as an adjunct to good surgical technique for the reduction of post-surgical adhesions in patients undergoing gynecological laparoscopic adhesiolysis.
|
|
|
|
|
- ADEPT® provides a temporary separation of peritoneal surfaces by hydroflotation as a result of maintaining a fluid reservoir. This colloidal osmotic action of icodextrin allows the retention of a reservoir of fluid within the peritoneal cavity for 3-4 days.1,3
- ADEPT® minimizes tissue apposition during the critical period of fibrin formation and mesothelial regeneration following surgery, thereby providing a barrier to adhesion formation.1
|
|
|
|
|
- Requires no significant change to surgical routine1,2
- Does not impair tissue handling and visibility of the surgical field1,2
|
|
|
 |
| Important Safety Information |
|
 |
|
|
|
ADEPT is for direct intraperitoneal administration only. NOT for intravenous (IV) administration. Adept is contraindicated in patients with known or suspected allergy to cornstarch based polymers e.g. icodextrin, or with maltose or isomaltose intolerance, or with glycogen storage disease. ADEPT is contraindicated in laparotomy, in cases involving bowel resection or repair, or appendectomy and in surgical cases with frank abdomino-pelvic infection.
There have been rare reports of sterile peritonitis following the use of icodextrin. Leakage of ADEPT from port sites may lead to wound healing complications; meticulous fascial closure may reduce leakage through laparoscopic port sites post-operatively. There have been rare reports of hypersensitivity reactions, pulmonary edema, pulmonary effusion and arrhythmia. Anaphylaxis has been reported in a few patients. Maltose metabolites of icodextrin may interefere with blood glucose measurement in diabetic patients who use rapid blood glucose systems that are not glucose specific.
In the pivotal study, the most frequently occurring treatment-related adverse events between surgeries were post procedural leaking from port sites, labial, vulvar or vaginal swelling and abdominal distention.
RX Only: For safe and proper use of this device, please refer to full device Instructions For Use.
|
|
|
|
|
- ADEPT® Adhesion Reduction Solution [4% Icodextrin] Instructions For Use, 6208501EH01.
- Sutton C., Minelli L., Garcia E., et al. Use of icodextrin 4% solution in the reduction of adhesion formation after gynaecological surgery, Gynecol Surg 2005 2: 287-296.
- Hosie K., Gilbert J.A., Kerr D., Brown C.B., Peers E.M. Fluid dynamics in man of an intraperitoneal drug delivery solution: 4% icodextrin. Drug Deliv 2001; 8: 9-12.
|
|
|
ADEPT is a registered trademark under license from Innovata plc.
|
|
|
|
|
|
|
|
|
|
|
Print this page
